Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/17/2017 02/21/2017 02/22/2017 02/23/2017 02/24/2017 Date
5.91(c) 5.84(c) 5.75(c) 5.89(c) 5.8(c) Last
902 291 719 020 524 669 603 462 472 030 Volume
-1.83% -1.18% -1.54% +2.43% -1.53% Change
More quotes
Financials ($)
Sales 2016 140 M
EBIT 2016 -64,4 M
Net income 2016 -73,5 M
Debt 2016 -
Yield 2016 -
Sales 2017 120 M
EBIT 2017 -71,4 M
Net income 2017 -79,5 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 3,33x
Capi. / Sales2017 3,90x
Capitalization 467 M
More Financials
Company
Spectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products.It targets non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma.It operates through... 
More about the company
Surperformance© ratings of Spectrum Pharmaceuticals,
Trading Rating : Investor Rating :
More Ratings
Latest news on SPECTRUM PHARMACEUTICALS,
02/16 SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the 2017 RBC Capital M..
01/09 SPECTRUM PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements an..
2016 SPECTRUM PHARMACEUTICALS : Research Reports Initiation on Biotech Stocks -- Incy..
2016 SPECTRUM PHARMACEUTICALS : Highlights Promising Preclinical Data Evaluating Pozi..
2016 SPECTRUM PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Nevada (Dec. 7)
2016 SPECTRUM PHARMACEUTICALS : Assigned Patent
2016 SPECTRUM PHARMACEUTICALS : Highlights Survival Advantage in a Case Match Control..
2016 SPECTRUM PHARMACEUTICALS : Highlights Five Abstracts on ROLONTIS™ (eflapeg..
2016 SPECTRUM PHARMACEUTICALS : Highlights Four Abstracts at the 58th Annual Meeting ..
2016 Continuing Challenges Hanmi Pharmaceutical Continues to Challenge for New Glo..
More news
Sector news : Biotechnology & Medical Research - NEC
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
02/14Want the latest upgrades & downgrades for $HCKT $BDC $TKR $SPPI $NFBK? Ch.. 
02/11Spectrum Pharmaceuticals's buy rating reiterated at Jefferies Group LLC.  
02/10Spectrum Pharmaceuticals, Inc. $SPPI Coverage Initiated at Jefferies Group LL.. 
02/05Spectrum Pharmaceuticals, Inc. $SPPI Stake Maintained by Sector Gamma AS  
01/19Get the latest news and updates for $HCKT $NFBK $BDC $TKR $SPPI automatically.. 
More tweets
Qtime:22
News from SeekingAlpha
2016 FDA rejects Spectrum Pharma's NDA for QAPZOLA
2016 Spectrum Pharma Q3 top line up 17%; net loss narrows
2016 Spectrum Pharmaceuticals beats by $0.23, misses on revenue
2016 After Hours Gainers / Losers
2016 Spectrum Pharmaceuticals beats on revenue
Advertisement
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Full-screen chart
Technical analysis trends SPECTRUM PHARMACE...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 9,38 $
Spread / Average Target 62%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Rajesh C. Shrotriya Chairman & Chief Executive Officer
Joseph G. Turgeon President & Chief Operating Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Stuart Mitchell Krassner Independent Non-Employee Director
Luigi Lenaz Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SPECTRUM PHARMACEUTICA..32.96%467
INCYTE CORPORATION21.62%24 852
QUINTILES IMS HOLDINGS..2.72%18 301
CELLTRION, INC.--.--%10 911
LONZA GROUP AG2.67%10 319
SEATTLE GENETICS, INC.19.52%8 939
More Results